Regeneron Reports Mixed Q4/FY25 Results, Strong Dupixent/EYLEA HD Growth, Key Regulatory Approvals

summarizeSummary

Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing strong growth in Dupixent and EYLEA HD sales, alongside significant regulatory approvals and pipeline advancements, despite a decline in overall EYLEA franchise sales.

check_boxKey Events

• Q4/FY25 Financial Performance

  Reported Q4 revenues increased 3% to $3.9 billion, with full year revenues up 1% to $14.3 billion. Q4 GAAP EPS decreased 2% to $7.86, while full year GAAP EPS increased 8% to $41.48.

• Dupixent & EYLEA HD Drive Growth

  Dupixent global net sales surged 34% to $4.9 billion in Q4, and EYLEA HD U.S. net sales increased 66% to $506 million, significantly offsetting a 28% decline in total EYLEA franchise U.S. sales.

• Multiple Regulatory Approvals

  Secured FDA approval for EYLEA HD in macular edema following retinal vein occlusion (RVO) and for monthly dosing flexibility, EC approval for Dupixent in chronic spontaneous urticaria (CSU), and FDA/EC approvals for Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).

• Pipeline Advancements & Investments

  Submitted Biologics License Applications (BLAs) for DB-OTO (gene therapy for hearing loss) and garetosmab (fibrodysplasia ossificans progressiva), and announced a $2 billion investment in a new manufacturing facility.

auto_awesomeAnalysis

Regeneron's latest earnings report highlights a strategic transition within its key product portfolio, with robust growth from Dupixent and EYLEA HD largely compensating for the decline in the legacy EYLEA product. The numerous regulatory approvals across its therapeutic areas, coupled with significant pipeline advancements and a substantial investment in manufacturing, underscore the company's commitment to long-term growth and innovation. Investors should monitor the continued market penetration of EYLEA HD and Dupixent, as well as the progress of newly submitted regulatory applications and the impact of the new manufacturing facility on future capacity and efficiency.